Genelux Says FDA Grants Fast Track Designation For Olvi-Vec

Immuno-oncology company Genelux Corp. (GNLX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.

Related Keywords

United States , , Acorn Baking Co , Drug Administration , Walmart , Black Friday , Country Gift Baskets , Acorn Baking , Cyber Monday , Fda , Us Food And Drug Administration , Benelux , Mmuno Oncology Company Genelux , Inlx , Lvi Vec , Olvimulogene Nanivacirepvec , Nprime Gog 3076 ,